Aquestive Therapeutics (NASDAQ:AQST) Trading Down 9.6% – Here’s Why

15 May 2026, 13:39 by Scott Moore · The Cerbat Gem

Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) fell 9.6% during trading on Friday . The company traded as low as $4.32 and last traded at $4.2750. 1,538,460 shares were traded during trading, a decline of 57% from the average session volume of 3,585,335 shares. The stock had previously closed at $4.73.

Analyst Ratings Changes

A number of brokerages have recently commented on AQST. Oppenheimer began coverage on Aquestive Therapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $8.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Monday, April 20th. Lake Street Capital set a $6.00 price target on Aquestive Therapeutics in a research report on Tuesday, February 3rd. Finally, Wall Street Zen cut Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $8.80.

Read Our Latest Research Report on AQST

Aquestive Therapeutics Stock Performance

The company has a market capitalization of $526.37 million, a P/E ratio of -6.94 and a beta of 1.50. The business has a 50 day moving average of $4.16 and a 200-day moving average of $4.78.

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. The company had revenue of $14.45 million for the quarter, compared to the consensus estimate of $10.90 million. As a group, equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Insider Activity at Aquestive Therapeutics

In related news, SVP Melina Cioffi sold 25,311 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $105,546.87. Following the sale, the senior vice president directly owned 274,867 shares in the company, valued at approximately $1,146,195.39. The trade was a 8.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Sherry Korczynski sold 15,741 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total value of $65,639.97. Following the sale, the insider owned 241,117 shares in the company, valued at approximately $1,005,457.89. The trade was a 6.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 395,690 shares of company stock worth $1,650,027 in the last 90 days. 6.81% of the stock is owned by company insiders.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Aquestive Therapeutics by 30.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock worth $31,651,000 after acquiring an additional 1,333,627 shares during the last quarter. State Street Corp increased its stake in Aquestive Therapeutics by 53.7% in the 4th quarter. State Street Corp now owns 2,462,778 shares of the company’s stock worth $15,910,000 after acquiring an additional 860,562 shares during the last quarter. Geode Capital Management LLC increased its stake in Aquestive Therapeutics by 13.4% in the 4th quarter. Geode Capital Management LLC now owns 2,368,092 shares of the company’s stock worth $15,301,000 after acquiring an additional 280,144 shares during the last quarter. Federated Hermes Inc. increased its stake in Aquestive Therapeutics by 159.4% in the 4th quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock worth $13,132,000 after acquiring an additional 1,249,044 shares during the last quarter. Finally, Millennium Management LLC increased its stake in Aquestive Therapeutics by 19.1% in the 4th quarter. Millennium Management LLC now owns 1,535,369 shares of the company’s stock worth $9,918,000 after acquiring an additional 246,040 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.